Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.78USD
25 Jul 2016
Change (% chg)

$0.04 (+0.11%)
Prev Close
$36.74
Open
$36.82
Day's High
$36.84
Day's Low
$36.51
Volume
3,843,959
Avg. Vol
8,888,141
52-wk High
$37.19
52-wk Low
$28.25

PFE.N

Chart for PFE.N

About

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor,... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $222,822.59
Shares Outstanding(Mil.): 6,064.85
Dividend: 0.30
Yield (%): 3.27

Financials

  PFE.N Industry Sector
P/E (TTM): 30.11 36.15 37.05
EPS (TTM): 1.22 -- --
ROI: 5.56 15.11 14.35
ROE: 11.65 16.17 15.56

BRIEF-Spark Therapeutics and Pfizer announce data from first cohort in Hemophilia B Phase 1/2 trial

* Spark Therapeutics and Pfizer announce updated data from first cohort in Hemophilia B phase 1/2 trial demonstrating consistent, sustained therapeutic levels of factor ix activity

Jul 25 2016

BRIEF-Bind Therapeutics says two bidders join Pfizer's stalking horse bid

* Bids are in addition to pfizer inc.'s initial stalking horse bid of approximately $20 million under section 363 of u.s. Bankruptcy code

Jul 25 2016

BRIEF-Pfizer gets WHO prequalification for multi-dose vial presentation of Prevenar 13

* Pfizer receives world health organization prequalification for multi-dose vial presentation of Prevenar 13

Jul 19 2016

DEALTALK-Old pharma sees new profit cure in cancer drugs

July 19 Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

Old pharma sees new profit cure in cancer drugs

Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

DEALTALK-Old pharma sees new profit cure in cancer drugs

July 19 Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

SoftBank to buy UK chip designer ARM in $32 billion cash deal

TOKYO/LONDON Japan's SoftBank will buy Britain's most valuable technology company ARM for $32 billion in cash, an audacious attempt to lead the next wave of digital innovation with a chip designer that powers the global mobile phone industry. | Video

Jul 18 2016

BRIEF-Pfizer publishes results from two Pivotal phase 3 studies of crisaborole topical ointment

* Pfizer announces publication of final results from two pivotal Phase 3 studies of crisaborole topical ointment in patients with mild to moderate atopic dermatitis

Jul 13 2016

FDA expands use of Pfizer's best-selling pneumonia vaccine

Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.

Jul 12 2016

FDA expands use of Pfizer's best-selling pneumonia vaccine

July 12 Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.

Jul 12 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.89 -0.14
Novartis AG (NOVN.S) CHF81.95 -0.25
Merck & Co., Inc. (MRK.N) $58.56 -0.26
Roche Holding Ltd. (ROG.S) CHF249.10 +0.30
Roche Holding Ltd. (RO.S) CHF250.75 +0.75
Abbott Laboratories (ABT.N) $43.41 +0.24
Bayer AG (BAYGn.DE) €92.53 -0.09
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.43 -0.08
AstraZeneca plc (AZN.L) 4,671.00p +17.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Wright Reports
$75.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.